EMA to endorse new dose-finding method to cut high Phase III failure rate
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is planning to endorse the use of a new methodology that could improve the way doses of new drugs are selected for use in confirmatory Phase III studies, and hopefully increase the chances of their making it through the final stages of development and onto the market.